Home Biosimilar Antibodies Immunology & Inflammation Immunology & Inflammation related Vibostolimab (anti-TIGIT)
For research use only. Not for use in humans.

Vibostolimab (anti-TIGIT)

Synonyms: MK-7684

Vibostolimab (anti-TIGIT, MK-7684) is a humanized monoclonal antibody that binds to the T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT), blocking the interaction between TIGIT and its ligands, CD112 and CD155, thereby activating T lymphocytes which help to destroy tumor cells.

Vibostolimab (anti-TIGIT)

Click to purchase the isotype control of Vibostolimab (anti-TIGIT)

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99% Protein concentration: 4.91mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Vibostolimab (anti-TIGIT, MK-7684) is a humanized monoclonal antibody that binds to the T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT), blocking the interaction between TIGIT and its ligands, CD112 and CD155, thereby activating T lymphocytes which help to destroy tumor cells.
References

Product Details

CAS No. 2231305-30-7
Molecular Weight 145 kD
Isotype Human IgG1, κ
Source CHO cells
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20 mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04165070 RECRUITING Drug: Carboplatin|Drug: Paclitaxel|Drug: Pemetrexed Carcinoma, Non-Small-Cell Lung Merck Sharp & Dohme LLC 2019-12-19 PHASE1; PHASE2
NCT06395090 WITHDRAWN Neoplasm Metastasis Merck Sharp & Dohme LLC 2025-01-15 PHASE1; PHASE2
NCT07667842 NOT_YET_RECRUITING Drug: D3L-002 Advanced Solid Tumor D3 Bio (Wuxi) Co., Ltd 2026-07-18 PHASE1
NCT02861573 ACTIVE_NOT_RECRUITING Drug: Olaparib 400 mg|Drug: Docetaxel 75 mg/m^2|Drug: Predni Metastatic Castration-Resistant Prostate Cancer Merck Sharp & Dohme LLC 2016-11-17 PHASE1; PHASE2
NCT06754501 ACTIVE_NOT_RECRUITING Drug: Atezolizumab|Drug: Tiragolumab Cancer M.D. Anderson Cancer Center 2025-04-11 PHASE2
NCT05845814 ACTIVE_NOT_RECRUITING Metastatic Urothelial Carcinoma; Urothelial Neoplasms Merck Sharp & Dohme LLC 2023-06-23 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-25)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.